{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:50:26Z","timestamp":1791910226191,"version":"4.3.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 AI177749"],"award-info":[{"award-number":["K23 AI177749"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K23AI177749-03"],"award-info":[{"award-number":["1K23AI177749-03"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clostridioides difficile infection (CDI) imposes a burden that extends well beyond the gastrointestinal tract, yet existing outcome measures only partially capture the patient experience. We used frontier large language models (LLMs) on patient and caregiver narratives at scale to describe how burden shifts with disease course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 189 testimonials from the Peggy Lillis Foundation corpus, sorted into 4 cohorts with recurrence (r) and fulminant (f) severity as axes (rfCDI, fCDI, rCDI, non-rfCDI). Two independent LLMs coded 8 thematic domains, 4 fulminant flags, 13 emerging semantic fields, the dominant dimension, and narrative arcs. Two physicians independently coded a subset for inter-rater reliability (PABAK, Gwet's AC1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment trajectory was the dominant theme in recurrent disease, whereas death and near-death dominated nonrecurrent fulminant narratives. Psychological burden was near-universal in fulminant disease (98.0% in rfCDI, 97.2% in fCDI). Caregiver and bereavement content concentrated in fCDI (66.7%). Diagnostic failure was frequent across recurrent cohorts (47.6\u201356.1%). Mentions of bacteriotherapy (fecal microbiota transplantation) concentrated in recurrent cohorts (60.2% rfCDI versus 5.6% fCDI). Financial, mental-health, and caregiver burdens were prominent and remain largely unaddressed by guidelines. Human-human reliability was substantial (PABAK 0.79 for semantic fields, 0.76 for domains); arc coding was least reliable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patient narratives reveal a course-dependent, multidimensional burden in CDI. Concrete gaps exist between what patients prioritize, what guidelines recommend, and what therapy access provides. Frontier-LLM coding, validated against clinicians, offers a reproducible route to translate these priorities into research, care, and policy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag650","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:33:24Z","timestamp":1791286404000},"source":"Crossref","is-referenced-by-count":0,"title":["The Patients\u2019 Voice in\n                    <i>Clostridioides difficile<\/i>\n                    Infection: Large Language Model-Assisted Thematic Analysis of Patient Testimonials"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-5271","authenticated-orcid":false,"given":"Javier A","family":"Villafuerte-G\u00e1lvez","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5510-9765","authenticated-orcid":false,"given":"Marco A","family":"Noriega","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Medicine, Mount Auburn Hospital, Harvard Medical School , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9363-5352","authenticated-orcid":false,"given":"Sena","family":"Cakir Colak","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mount Auburn Hospital, Harvard Medical School , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-8877","authenticated-orcid":false,"given":"Carl V","family":"Crawford","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Weill Cornell Medicine , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026101312140825400_ofag650-B1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. Burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N Engl J Med"},{"key":"2026101312140825400_ofag650-B2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"key":"2026101312140825400_ofag650-B3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1586\/egh.10.48","article-title":"The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings","volume":"4","author":"Khanna","year":"2010","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026101312140825400_ofag650-B4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1017\/ice.2023.262","article-title":"Potential underreporting of treated patients using a Clostridioides difficile testing algorithm that screens with a nucleic acid amplification test","volume":"45","author":"Guh","year":"2024","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026101312140825400_ofag650-B5","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1017\/ash.2025.180","article-title":"Impact of a multi-step testing algorithm on hospital-onset Clostridioides difficile rates and clinical outcomes","volume":"5","author":"Moffa","year":"2025","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2026101312140825400_ofag650-B6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/cid\/civ958","article-title":"Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection","volume":"62","author":"Sheitoyan-Pesant","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026101312140825400_ofag650-B7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archsurg.2009.51","article-title":"Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality","volume":"144","author":"Sailhamer","year":"2009","journal-title":"Arch Surg"},{"key":"2026101312140825400_ofag650-B8","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf033","article-title":"Defining fulminant Clostridioides difficile infections: assessing the utility of hypotension as a diagnostic criterion","volume":"12","author":"Chua","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026101312140825400_ofag650-B9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"key":"2026101312140825400_ofag650-B10","author":"American Society of Health-System Pharmacists"},{"key":"2026101312140825400_ofag650-B11","author":"Center for Biologics Evaluation and Research"},{"key":"2026101312140825400_ofag650-B12","author":"Center for Biologics Evaluation and Research"},{"key":"2026101312140825400_ofag650-B13","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s40121-025-01169-4","article-title":"Budget impact analysis of fecal microbiota spores, live-brpk (formerly SER-109) for recurrent Clostridioides difficile infection in the United States","volume":"14","author":"Wilson","year":"2025","journal-title":"Infect Dis Ther"},{"key":"2026101312140825400_ofag650-B14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MCG.0000000000000473","article-title":"Development and validation of a Clostridium difficile health-related quality-of-life questionnaire","volume":"50","author":"Garey","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"2026101312140825400_ofag650-B15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.53570","article-title":"Assessment of quality of life among patients with recurrent Clostridioides difficile infection treated with investigational oral microbiome therapeutic SER-109: secondary analysis of a randomized clinical trial","volume":"6","author":"Garey","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026101312140825400_ofag650-B16","article-title":"Effect of fecal microbiota, live-jslm (REBYOTA [RBL]) on health-related quality of life in patients with recurrent Clostridioides difficile infection: results from the PUNCH CD3 clinical trial","volume":"10","author":"Garey","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026101312140825400_ofag650-B17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s41687-022-00456-9","article-title":"Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life","volume":"6","author":"Hengel","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2026101312140825400_ofag650-B18","doi-asserted-by":"crossref","DOI":"10.1177\/17562848251392102","article-title":"Patient-reported benefits of colonoscopically administered microbiota restoration therapy: a qualitative study of adult patients with recurrent Clostridioides difficile infection","volume":"18","author":"McCool-Myers","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"2026101312140825400_ofag650-B19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026101312140825400_ofag650-B20","author":"Food and Drug Administration"},{"key":"2026101312140825400_ofag650-B21","doi-asserted-by":"crossref","first-page":"e85960","DOI":"10.2196\/85960","article-title":"Topic-aware summarization of lived health care experiences: large language model evaluation study","volume":"14","author":"Bilalpur","year":"2026","journal-title":"JMIR Med Inform"},{"key":"2026101312140825400_ofag650-B22","first-page":"503","article-title":"Using large language models for sentiment analysis of health-related social media data: empirical evaluation and practical tips","volume":"2024","author":"He","year":"2024","journal-title":"AMIA Annu Symp Proc"},{"key":"2026101312140825400_ofag650-B23","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1093\/cid\/ciab826","article-title":"Ultrasensitive and quantitative toxin measurement correlates with baseline severity, severe outcomes, and recurrence among hospitalized patients with Clostridioides difficile infection","volume":"74","author":"Alonso","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026101312140825400_ofag650-B24","doi-asserted-by":"crossref","DOI":"10.7208\/chicago\/9780226260037.001.0001","volume-title":"The wounded storyteller: body, illness, and ethics","author":"Frank","year":"1995"},{"key":"2026101312140825400_ofag650-B25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/PPA.S229539","article-title":"Patient experiences with Clostridioides difficile infection: results of a Canada-wide survey","volume":"14","author":"Vent-Schmidt","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"2026101312140825400_ofag650-B26","doi-asserted-by":"crossref","first-page":"otaf007","DOI":"10.1093\/crocol\/otaf007","article-title":"Understanding the lived experience after colectomy and ileal pouch-anal anastomosis for ulcerative colitis: a qualitative study","volume":"7","author":"Barnes","year":"2025","journal-title":"Crohns Colitis 360"},{"key":"2026101312140825400_ofag650-B27","doi-asserted-by":"crossref","first-page":"e81643","DOI":"10.2196\/81643","article-title":"Engaging patient and caregiver partners in codeveloping a patient educational video for improving Clostridioides difficile infection education: participatory co-design study","volume":"10","author":"Patel","year":"2026","journal-title":"JMIR Form Res"},{"key":"2026101312140825400_ofag650-B28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0895-4356(93)90018-V","article-title":"Bias, prevalence and kappa","volume":"46","author":"Byrt","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"2026101312140825400_ofag650-B29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1348\/000711006X126600","article-title":"Computing inter-rater reliability and its variance in the presence of high agreement","volume":"61","author":"Gwet","year":"2008","journal-title":"Br J Math Stat Psychol"},{"key":"2026101312140825400_ofag650-B30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ Psychol Meas"},{"key":"2026101312140825400_ofag650-B31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"2026101312140825400_ofag650-B32","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211016248","article-title":"Epidemiology of community-acquired and recurrent Clostridioides difficile infection","volume":"14","author":"Fu","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2026101312140825400_ofag650-B33","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27 Suppl 2","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026101312140825400_ofag650-B34","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026101312140825400_ofag650-B35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12879-023-08096-0","article-title":"The burden of CDI in the United States: a multifactorial challenge","volume":"23","author":"Feuerstadt","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2026101312140825400_ofag650-B36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","article-title":"AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases","volume":"166","author":"Peery","year":"2024","journal-title":"Gastroenterology"},{"key":"2026101312140825400_ofag650-B37","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2026101312140825400_ofag650-B38","doi-asserted-by":"crossref","first-page":"e1195","DOI":"10.1093\/cid\/ciac554","article-title":"Validation of a health-related quality of life questionnaire in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a phase 3 randomized trial","volume":"76","author":"Lapin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026101312140825400_ofag650-B39","doi-asserted-by":"crossref","first-page":"ooaf126","DOI":"10.1093\/jamiaopen\/ooaf126","article-title":"Leveraging ChatGPT for thematic analysis of medical best practice advisory data","volume":"8","author":"Jeong","year":"2025","journal-title":"JAMIA Open"},{"key":"2026101312140825400_ofag650-B40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41687-020-0179-1","article-title":"Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey","volume":"4","author":"Lurienne","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2026101312140825400_ofag650-B41","unstructured":"Villafuerte-G\u00e1lvez JA. \u00a0Replication Package\u2014The Patients\u2019 Voice in Clostridioides difficile Infection: LLM-Assisted Thematic Analysis of Patient Testimonials [dataset]. Zenodo \u00a02026. Available at: 10.5281\/zenodo.21262959."}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag650\/71719633\/ofag650.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag650\/71719633\/ofag650.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag650\/71719633\/ofag650.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:14:16Z","timestamp":1791908056000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag650\/8885718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag650","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,29]]},"article-number":"ofag650"}}